Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Venetoclax

FDA-approved product (tablet, oral), marketed as Venclexta, Venetoclax.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Venetoclax
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
BCL-2 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Venetoclax in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Venetoclax with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece

    NCT05317494 · start 2022-05-26

    Registered record
    Registry ID
    NCT05317494
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-05-26
    Completion
    2026-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

    NCT05282719 · start 2022-04

    Registered record
    Registry ID
    NCT05282719
    Conditions
    Myelodysplastic/Myeloproliferative Neoplasms; Adult
    Interventions
    venetoclax combined with azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-04
    Completion
    2023-02
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic/Myeloproliferative Neoplasms; Adult
    Interventionvenetoclax combined with azacitidine
    PhasePhase 2
    Registry statusUnknown

  • Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    NCT04840602 · start 2022-01-05

    Registered record
    Registry ID
    NCT04840602
    Conditions
    Lymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Ibrutinib; Positron Emission Tomography; Rituximab; Venetoclax; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-01-05
    Completion
    2028-03-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +5 more
    PhasePhase 2
    Registry statusRecruiting

  • A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    NCT04965493 · start 2021-09-20

    Registered record
    Registry ID
    NCT04965493
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Venetoclax; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-09-20
    Completion
    2027-10
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionPirtobrutinib; Venetoclax; Rituximab
    PhasePhase 3
    Registry statusActive not recruiting

  • Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

    NCT04666649 · start 2021-03-10

    Registered record
    Registry ID
    NCT04666649
    Conditions
    Relapsed or Refractory Acute Myeloid Leukemia
    Interventions
    Venetoclax and pegcrisantaspase
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-10
    Completion
    2025-05-23
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Acute Myeloid Leukemia
    InterventionVenetoclax and pegcrisantaspase
    PhasePhase 1
    Registry statusCompleted

  • Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

    NCT04550442 · start 2020-09-04

    Registered record
    Registry ID
    NCT04550442
    Conditions
    Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome
    Interventions
    Azacitidine; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-09-04
    Completion
    2026-05-29
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome +1 more
    InterventionAzacitidine; Venetoclax
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

    NCT04188405 · start 2020-05-17

    Registered record
    Registry ID
    NCT04188405
    Conditions
    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions
    Decitabine; Ponatinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-05-17
    Completion
    2026-06-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Myeloid Leukemia +3 more
    InterventionDecitabine; Ponatinib; Venetoclax
    PhasePhase 2
    Registry statusCompleted

  • Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

    NCT04128501 · start 2020-05-05

    Registered record
    Registry ID
    NCT04128501
    Conditions
    Acute Bilineal Leukemia; Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia; T Acute Lymphoblastic Leukemia; Therapy-Related Acute Myeloid Leukemia
    Interventions
    Azacitidine; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-05-05
    Completion
    2026-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bilineal Leukemia; Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia +2 more
    InterventionAzacitidine; Venetoclax
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

    NCT04253314 · start 2020-03-13

    Registered record
    Registry ID
    NCT04253314
    Conditions
    Acute Myeloid Leukemia (AML)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-03-13
    Completion
    2023-02-16
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML

    NCT07318662 · start 2020-01-01

    Registered record
    Registry ID
    NCT07318662
    Conditions
    MDS; CMML
    Interventions
    Venetoclax
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2020-01-01
    Completion
    2027-03-30
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDS; CMML
    InterventionVenetoclax
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

    NCT03557619 · start 2019-07-30

    Registered record
    Registry ID
    NCT03557619
    Conditions
    Hematologic Malignancies
    Interventions
    Venetoclax; ethinyl estradiol/levonorgestrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2019-07-30
    Completion
    2026-03-21
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancies
    InterventionVenetoclax; ethinyl estradiol/levonorgestrel
    PhasePhase 1
    Registry statusUnknown

  • A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

    NCT03873857 · start 2019-02-25

    Registered record
    Registry ID
    NCT03873857
    Conditions
    Chronic Lymphocytic Leukemia (CLL); Cancer
    Interventions
    Venetoclax
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-02-25
    Completion
    2022-09-12
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia (CLL); Cancer
    InterventionVenetoclax
    PhaseNot recorded
    Registry statusCompleted

  • Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

    NCT03737981 · start 2019-01-31

    Registered record
    Registry ID
    NCT03737981
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Ibrutinib; Obinutuzumab; Observation Activity; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-01-31
    Completion
    2026-12-29
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionIbrutinib; Obinutuzumab; Observation Activity; Venetoclax
    PhasePhase 3
    Registry statusActive not recruiting

  • Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

    NCT03735875 · start 2019-01-25

    Registered record
    Registry ID
    NCT03735875
    Conditions
    Acute Myeloid Leukemia With FLT3/ITD Mutation; Recurrent Acute Myeloid Leukemia; Refractory Acute Leukemia
    Interventions
    Quizartinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2019-01-25
    Completion
    2023-07-26
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia With FLT3/ITD Mutation; Recurrent Acute Myeloid Leukemia; Refractory Acute Leukemia
    InterventionQuizartinib; Venetoclax
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

    NCT03787264 · start 2019-01-14

    Registered record
    Registry ID
    NCT03787264
    Conditions
    Chronic Lymphoid Leukemia
    Interventions
    Bendamustine; Obinutuzumab; Acalabrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-01-14
    Completion
    2023-09-26
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphoid Leukemia
    InterventionBendamustine; Obinutuzumab; Acalabrutinib; Venetoclax
    PhasePhase 2
    Registry statusCompleted